Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$24.55 USD
-0.92 (-3.61%)
Updated May 24, 2024 04:00 PM ET
After-Market: $24.57 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Mirum Pharmaceuticals, Inc. [MIRM]
Reports for Purchase
Showing records 61 - 80 ( 99 total )
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Recap; Eventful Months Ahead With Two Regulatory Filing for Maralixibat in PFIC2 and ALGS; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Maralixibat Granted Orphan Drug Designation for Biliary Atresia; Phase 2 Study Nears Initiation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EVERSANA Partnership Enables Mirum to Focus on Key Prescriber Interactions; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Maralixibat Rolling NDA Submission for ALGS Begins; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Recap: Regulatory Path for Maralixibat in PFIC2 Secured in Europe; U.S. Path Is Next; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Potential Quick Path to NDA Filing in PFIC2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Which Orphan Companies to See and Why at Our 32nd Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Part 2: "Must-See" Companies at JPM (Mkt. Cap. $100M-$499M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y